Mabion

Mabion S.A. is a publicly traded Polish biopharmaceutical company, founded in 2007. Mabion is a European-based CDMO specializing in complex biologics. Mabion specializes in small to mid-sized projects at various stages of development – from early-stage development of stable cell lines to commercial manufacturing. Mabion’s core competencies include monoclonal antibody development technologies, recombinant protein production (using mammalian and insect cell expression systems), advanced analytics, and manufacturing of both Drug Substance and Drug Product. The company operates in compliance with globally recognized quality standards, including GMP, and ISO. Mabion employs over 200 highly qualified professionals, including scientists, engineers, and experts in quality, manufacturing, and analytical development for biologics. The company is committed to accelerating access to innovative therapies through science-led collaboration. The company's mission is to be a trusted global partner for the development and manufacturing of biologic medicines.